« BACK

Pharmacology



Results 1 - 11 of 11.


Pharmacology - Health - 18.12.2018
Buruli Ulcer: Promising New Drug Candidate Against a Forgotten Disease
Buruli Ulcer: Promising New Drug Candidate Against a Forgotten Disease
Buruli ulcer is a neglected tropical disease (NTD) resulting in debilitating skin lesions, disabilities and stigmatisation. The current antibiotic treatment is long and has severe adverse side effects. Researchers from the Swiss Tropical and Public Health Institute (Swiss TPH) together with colleagues from Singapore have discovered a highly effective compound against Buruli ulcer which has the potential to become a powerful alternative to the existing treatment options.

Health - Pharmacology - 14.12.2018
Modelling for New Schistosomiasis Treatment Thresholds
Modelling for New Schistosomiasis Treatment Thresholds
Schistosomiasis is a parasitic worm infection affecting 250 million people globally. The current prevalence thresholds for preventive chemotherapy of schistosomiasis are based on the Kato-Katz method using stool samples. A new more sensitive point-of-care urine test is now available in particular for settings with low prevalence.

Pharmacology - Health - 11.12.2018
Lethal combination: Drug cocktail turns off the juice to cancer cells
Lethal combination: Drug cocktail turns off the juice to cancer cells
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth - this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, recently published in "Cell Reports", the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

Health - Pharmacology - 06.12.2018
Statins Overprescribed for Primary Prevention
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease. A study by the University of Zurich now shows that this measure is recommended too often, as current guidelines fail to take into account the risks of side effects. Even healthy people who don't suffer from a cardiovascular disease are prescribed cholesterol-lowering drugs, known as statins, if they meet certain risk criteria.

Health - Pharmacology - 28.11.2018
New Stem-Cell Therapy to Improve Fight against Leukemia
Stem-cell transplantation is an effective form of therapy to fight leukemia. In many cases, however, the transferred immune cells of the donor also attack the recipients' healthy tissue ' often with fatal consequences. Researchers at the University of Zurich have now identified a molecule that plays a key role in this process.

Pharmacology - Health - 19.11.2018
From Receptor Structure to New Osteoporosis Drugs
From Receptor Structure to New Osteoporosis Drugs
Researchers have determined the three-dimensional structure of a receptor that controls the release of calcium from bones. The receptor is now one of the main candidates for developing new drugs to treat osteoporosis. Knowing the receptor's blueprint will be instrumental for designing drugs that could even help to rebuild bones.

Health - Pharmacology - 22.10.2018
Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer Head-to-head phase III study of Alecensa versus crizotinib in Asian patient population showed a reduction in the risk of disease worsening or death by 78% Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system

Health - Pharmacology - 02.10.2018
Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS Data reinforce importance of early initiation and continuation of OCREVUS treatment New analyses highlight the need for active treatment in underrepresented populations, such as primary progressive MS (PPMS) patients with more advanced disability and relapsing MS (RMS) patients of African descent Roche

Pharmacology - Health - 30.08.2018
Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in treated bleeds in an intra-patient comparison Hemlibra is currently under Priority Review by the FDA for people with haemophilia A without factor VIII inhibitors Roche today announced that pivotal data from the phase III HAVE

Pharmacology - Health - 15.06.2018
New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
After a follow-up time of nearly five years the CLL11 study shows a 51% reduction in the risk of disease progression or death with Gazyva/Gazyvaro compared to MabThera/Rituxan The final analysis reports a clinically meaningful overall survival benefit is seen for Gazyva/Gazyvaro compared to MabThera/Rituxan when combined with chlorambucil These data highlight the superiority of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatmen

Life Sciences - Pharmacology - 16.04.2018
Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer's disease, Huntington's disease, Spinal Muscular Atrophy and Duchenne Muscular Dystrophy will highlight the strength of Roche's neuroscience pipeline Roche announced today that new data on